“…As the precise nature of this drug's effect on the cells might be still not fully understood, it is important to create the correct experimental context, as TMZ is also an important component of complex combination therapies, such as the RIST (rapamycin, irinotecan, sunitinib, TMZ) protocol or the CUSP9 (coordinated undermining of survival paths with nine repurposed drugs) approach [20,21]. Importantly, in this context TMZ has been shown, even at low concentrations, to enhance the response of GB cells to radiation, or, in combination with a pharmacological PI3K/mTOR inhibitor, to break the increased apoptosis-resistance of certain GB cell populations [19,22].…”